Q-omics provides the consensus-scored PNLIP profile across patient tissues and cancer cell-line models. PNLIP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PNLIP is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PNLIP RNA expression shows 6,822 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, HNSC, and PDAC as cancer lineages where PNLIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNLIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNLIP survival associations across molecular data types. PNLIP RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNLIP RNA expression–survival associations across cancer types. High PNLIP expression shows unfavorable associations in KICH, CESC, UCS, KIRC, GBM and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PNLIP RNA expression.
This table summarizes PNLIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PNLIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNLIP shows higher tumor expression in HNSC, PRAD, LIHC and BRCA. The HNSC box plot shows higher PNLIP RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .022).
This table shows molecular features associated with PNLIP in patient tissues and cancer cell lines. In patient samples, PNLIP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PNLIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and STOMACH.
